Skip to main content

Lymphoma

Immunotherapy with PD-1 Inhibitors the Newest Breakthrough in Hodgkin Lymphoma

Rituximab Maintenance Extends Remission in Follicular Lymphoma, but Overall Survival Unaffected

Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit

PI3K Inhibitors Main Focus of Drug Pipeline for Lymphoma

Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas

PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes

Ara-C Should Be Part of Conditioning Regimen in Young Patients with Mantle-Cell Lymphoma

Optimal Length of Treatment of Non-Hodgkin Lymphoma Debated

HBV Screening before Lymphoma Treatment Improves Outcomes, Is Cost-Effective

1
2
3

Page 3 of 3
Results 21 - 29 of 29